Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro
- PMID: 15109248
- DOI: 10.1021/bi0361766
Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro
Abstract
SARS (severe acute respiratory syndrome) is caused by a newly discovered coronavirus. A key enzyme for the maturation of this virus and, therefore, a target for drug development is the main protease 3CL(pro) (also termed SARS-CoV 3CL(pro)). We have cloned and expressed in Escherichia coli the full-length SARS-CoV 3CL(pro) as well as a truncated form containing only the catalytic domains. The recombinant proteins have been characterized enzymatically using a fluorescently labeled substrate; their structural stability in solution has been determined by differential scanning calorimetry, and novel inhibitors have been discovered. Expression of the catalytic region alone yields a protein with a reduced catalytic efficiency consistent with the proposed regulatory role of the alpha-helical domain. Differential scanning calorimetry indicates that the alpha-helical domain does not contribute to the structural stability of the catalytic domains. Analysis of the active site cavity reveals the presence of subsites that can be targeted with specific chemical functionalities. In particular, a cluster of serine residues (Ser139, Ser144, and Ser147) was identified near the active site cavity and was susceptible to being targeted by compounds containing boronic acid. This cluster is highly conserved in similar proteases from other coronaviruses, defining an attractive target for drug development. It was found that bifunctional aryl boronic acid compounds were particularly effective at inhibiting the protease, with inhibition constants as strong as 40 nM. Isothermal titration microcalorimetric experiments indicate that these inhibitors bind reversibly to 3CL(pro) in an enthalpically favorable fashion, implying that they establish strong interactions with the protease molecule, thus defining attractive molecular scaffolds for further optimization.
Similar articles
-
Long-range cooperative interactions modulate dimerization in SARS 3CLpro.Biochemistry. 2006 Dec 19;45(50):14908-16. doi: 10.1021/bi0616302. Biochemistry. 2006. PMID: 17154528 Free PMC article.
-
Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.J Biol Chem. 2015 Aug 7;290(32):19403-22. doi: 10.1074/jbc.M115.651463. Epub 2015 Jun 8. J Biol Chem. 2015. PMID: 26055715 Free PMC article.
-
Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.Antiviral Res. 2011 Nov;92(2):204-12. doi: 10.1016/j.antiviral.2011.08.001. Epub 2011 Aug 11. Antiviral Res. 2011. PMID: 21854807 Free PMC article.
-
Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.Molecules. 2020 Aug 27;25(17):3920. doi: 10.3390/molecules25173920. Molecules. 2020. PMID: 32867349 Free PMC article. Review.
-
The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29. Antiviral Res. 2015. PMID: 25554382 Free PMC article. Review.
Cited by
-
Shuffling multivariate adaptive regression splines and adaptive neuro-fuzzy inference system as tools for QSAR study of SARS inhibitors.J Pharm Biomed Anal. 2009 Dec 5;50(5):853-60. doi: 10.1016/j.jpba.2009.07.009. Epub 2009 Jul 14. J Pharm Biomed Anal. 2009. PMID: 19665859 Free PMC article.
-
The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain.FEBS J. 2006 Mar;273(5):1035-45. doi: 10.1111/j.1742-4658.2006.05130.x. FEBS J. 2006. PMID: 16478476 Free PMC article.
-
"Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs.Biochem Biophys Res Commun. 2004 Aug 20;321(2):370-8. doi: 10.1016/j.bbrc.2004.06.155. Biochem Biophys Res Commun. 2004. PMID: 15358186 Free PMC article.
-
Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.RSC Adv. 2020 Jul 17;10(45):26895-26916. doi: 10.1039/d0ra05821a. eCollection 2020 Jul 15. RSC Adv. 2020. PMID: 35515773 Free PMC article. Review.
-
Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review.RSC Adv. 2020 Jul 29;10(47):28287-28299. doi: 10.1039/d0ra04395h. eCollection 2020 Jul 27. RSC Adv. 2020. PMID: 35519094 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous